This is a preprint of an article accepted for publication in Luminescence:
Various 1,2-dioxetane derivatives represented by one bearing a spiroadamantyl group joined at the 3-position and a phenol phosphate at the 4-position have been synthesized and applied for clinical usage and chemiluminescence enzyme immunoassay (CLEIA). These 1,2-dioxetanes do not, however, necessarily satisfy the demands, namely high thermal stability, easiness for handling, and high light yield, to use in the field of clinical applications. Upon an extensive study, we have reached a new 1,2-dioxetane derivative having a fused furan ring and a bulky substituent e.g. t-Bu group and phenol phosphate with superiority to conventional 1,2-dioxetane derivative. Using such 1,2-dioxetane derivative, we have realized new CLEIA system in combination with an enhancer, a tetra-alkyl phosphonium derivative together with fluorescein, and found that this substrate is quite stable and has a very high light emitting efficiency. Thus, this substrate was stable and intact for more than one month at 40°C and for more than one year at 10°C. Furthermore, this substrate was found to have light yield more than six times higher than that for Lumi Phos 530 (AMPPD) at 5 minutes end point by alkaline phosphatase assay.
In conclusion, our substrate comprised of a new 1,2-dioxetane and an enhancer was found to have excellent characteristics with a high thermal stability and a very high light yield which can be well applied in clinical usage.
CLEIA using new chemiluminescence substrate showed highly sensitive immunoassay with TSH even less than 0.001 µIU/mL. We will discuss further in detail about our substrate and CLEIA results.
